In 2023, around 72,776 people in the United States died from a drug overdose that involved fentanyl. This was the second-highest number of fentanyl overdose deaths ever recorded in the United States, and a significant increase from the number of deaths reported in 2019. Fentanyl overdoses are now the driving force behind the opioid epidemic, accounting for the majority of overdose deaths in the United States. What is fentanyl? Fentanyl is an extremely potent synthetic opioid similar to morphine, but more powerful. It is a prescription drug but is also manufactured illegally and is sometimes mixed with other illicit drugs such as heroin and cocaine, often without the user’s knowledge. The potency of fentanyl makes it very addictive and puts users at a high risk for overdose. Illegally manufactured fentanyl has become more prevalent in the United States in recent years, leading to a huge increase in drug overdose deaths. In 2022, the rate of drug overdose death involving fentanyl was 22.7 per 100,000 population, compared to a rate of just one per 100,000 population in the year 2013. Fentanyl overdoses by gender and race/ethnicity As of 2022, the rate of drug overdose deaths involving fentanyl in the United States is over two times higher among men than women. Rates of overdose death involving fentanyl were low for both men and women until around the year 2014 when they began to quickly increase, especially for men. In 2022, there were around 19,880 drug overdose deaths among women that involved fentanyl compared to 53,958 such deaths among men. At that time, the rate of fentanyl overdose deaths was highest among non-Hispanic American Indian or Alaska Natives and lowest among non-Hispanic Asians. However, from the years 2014 to 2018, non-Hispanic whites had the highest fentanyl overdose death rates.

A. SUMMARY This dataset includes unintentional drug overdose death rates by race/ethnicity by year. This dataset is created using data from the California Electronic Death Registration System (CA-EDRS) via the Vital Records Business Intelligence System (VRBIS). Substance-related deaths are identified by reviewing the cause of death. Deaths caused by opioids, methamphetamine, and cocaine are included. Homicides and suicides are excluded. Ethnic and racial groups with fewer than 10 events are not tallied separately for privacy reasons but are included in the “all races” total.

Unintentional drug overdose death rates are calculated by dividing the total number of overdose deaths by race/ethnicity by the total population size for that demographic group and year and then multiplying by 100,000. The total population size is based on estimates from the US Census Bureau County Population Characteristics for San Francisco, 2022 Vintage by age, sex, race, and Hispanic origin.

These data differ from the data shared in the Preliminary Unintentional Drug Overdose Death by Year dataset since this dataset uses finalized counts of overdose deaths associated with cocaine, methamphetamine, and opioids only.

B. HOW THE DATASET IS CREATED This dataset is created by copying data from the Annual Substance Use Trends in San Francisco report from the San Francisco Department of Public Health Center on Substance Use and Health.

C. UPDATE PROCESS This dataset will be updated annually, typically at the end of the year.

D. HOW TO USE THIS DATASET N/A

E. RELATED DATASETS Overdose-Related 911 Responses by Emergency Medical Services Preliminary Unintentional Drug Overdose Deaths San Francisco Department of Public Health Substance Use Services

F. CHANGE LOG

• 12/16/2024 - Updated with 2023 data. Asian/Pacific Islander race/ethnicity group was changed to Asian.
• 12/16/2024 - Past year totals by race/ethnicity were revised after obtaining accurate race/ethnicity for some decedents that were previously marked as “unknown” race/ethnicity.

West Virginia is currently the state with the highest drug overdose death rate in the United States, with 82 deaths per 100,000 population in 2023. Although West Virginia had the highest drug overdose death rate at that time, California was the state where the most people died from drug overdose. In 2023, around ****** people in California died from a drug overdose. The main perpetrator Opioids account for the majority of all drug overdose deaths in the United States. Opioids include illegal drugs such as heroin, legal prescription drugs like oxycodone, and illicitly manufactured synthetic drugs like fentanyl. The abuse of opioids has increased in recent years, leading to an increased number of drug overdose deaths. The death rate from heroin overdose hit an all-time high of *** per 100,000 population in 2016 and 2017, but has decreased in recent years. Now, illicitly manufactured synthetic opioids such as fentanyl account for the majority of opioid overdose deaths in the United States. Opioid epidemic The sharp rise in overdose deaths from opioids has led many to declare the United States is currently experiencing an opioid epidemic or opioid crisis. The causes of this epidemic are complicated but involve a combination of a rise in dispensed prescriptions, irresponsible marketing from pharmaceutical companies, a lack of physician-patient communication, increased social acceptance of prescription drugs, and an increased supply of cheap and potent heroin on the streets.

In 2022, those aged between 35 and 44 years had the highest number of drug overdose deaths in the United States, with 27,583 deaths. Opioids are the main driver of overdose deaths in the United States. This statistic presents the number of drug overdose deaths in the U.S. from 2013 to 2022, by age group.

The graph illustrates the number of deaths from fentanyl in the United States from 1999 to 2022. The x-axis represents the years, spanning from '99 to '22, while the y-axis displays the annual number of fentanyl-related fatalities. Over this 24-year period, deaths rise dramatically from 730 in 1999 to a peak of 73,838 in 2022. Notable milestones include an increase to 1,742 deaths in 2005, a significant jump to 9,580 in 2015, and a sharp escalation to 70,601 deaths by 2021. The data reveals a consistent and severe upward trend in fentanyl-related deaths, particularly accelerating in the mid-2010s. This information is presented in a line graph format, effectively highlighting the dramatic increase in fatalities due to fentanyl across the United States over the specified years.

According to Cognitive Market Research, the Global Opioids Market Size will be USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.

  The global opioid market will expand significantly by XX% CAGR between 2024 and 2030.
  The Pain Relief segment accounts for the largest market share and is anticipated to a healthy growth over the approaching years.
  The hospital pharmacies had a market share of about XX% in 2023.
  The Extended Release /Long-Acting Opioids holds the largest share and is expected to grow in the coming years as well.
  The injectable segment is the market's largest contributor and is anticipated to expand at a CAGR of XX% during the projected period.
  The oxycodone segment holds the largest share and is expected to grow in the coming years as well.
  North America region dominated the market and accounted for the highest revenue of XX% in 2023 and it is projected that it will grow at a CAGR of XX% in the future.

Market Dynamics of the Opioids

Rising prevalence of chronic pain conditions globally

The increased prescription of painkillers during post-operative procedures and an increase in patients with terminally chronic pain or diseases including HIV, and severe cough brought on by lung infections are two causes that are anticipated to increase opioid use as a pain reliever. Chronic pain affects an estimated 20% of the global population, with conditions such as arthritis, cancer, and lower back pain contributing to the growing demand for effective pain management solutions. In the past, it resulted in a demand surge for opioids and boosted growth. Another factor for the growth of the opioid drug market is the spike in the number of surgeries. According to the National Health Interview Survey (NHIS) conducted by the Centers for Disease Control and Prevention (CDC) in 2019, the prevalence of high-impact chronic pain in the United States was 7.4 percent.

(Source-https://www.cdc.gov/nchs/data/databriefs/db390-H.pdf)

The aging population’s vulnerability is at high risk of chronic diseases such as cardiovascular diseases, arthritis, and cancer due to the high comorbid conditions. Declining fertility and mortality rates are some factors contributing to the geriatric population's rise. The impact of chronic pain increases with age and is highest among adults aged 65 years and above. Therefore, the rising geriatric population is anticipated to increase the demand for opioid drugs to manage chronic pain. According to the World Health Organization (WHO), the geriatric population increased from 1.0 million in 2020 to 1.4 million in 2021.

(Source-https://www.who.int/news-room/fact-sheets/detail/ageing-and-health)

Opioid addiction and its side effects pose significant challenges to the market

One of the major challenges for this market is the high potential for abuse and addiction, physicians have scaled back their pain management prescriptions, decreasing global scales. The rising prevalence of opioid abuse is expected to stifle market growth, as practitioners are hesitant to prescribe opioids as pain relievers. The patient may become tolerant and need more and more drugs to achieve the effect of smoothing the pain. Moreover, using opioids for an extended period can develop a dependency, and after leaving the drug, the patient may suffer from withdrawal symptoms such as anxiety, irritability, drug cravings, tremors (shaking), and others. The heightened regulatory scrutiny has resulted in stricter guidelines for prescribing opioids, impacting accessibility for patients in genuine need of pain relief. Regulatory changes often aim to strike a balance between ensuring access for patients and preventing misuse. The forecasted period illustrates a decrease in the opioid market growth due to the adversities and the negative effects of opioids. Researchers and experts have considered this and are making constant efforts to reduce and minimize the negative side effects of opioids. As per the record, drug overdose in the year 2018, had 657 deaths.

(Source-https://www.mass.gov/doc/opioid-related-overdose-deaths-among-ma-residents-august-2018/download)

Furthermore, the Millennium Health's Signals report (2020) revealed that there was a rise in non-prescribe...

Snapshot img

What is the Size of Opioid Rescue Products Market?

The opioid rescue products market size is forecast to increase by USD 1.69 billion, at a CAGR of 11.6% between 2023 and 2028. The market is experiencing significant growth due to the escalating opioid overdose crisis in the US. According to the National Institute on Drug Abuse, over 130 Americans die daily from an opioid overdose. In response, the opioid industry is focusing on the development and approval of new drugs to address this public health concern. For instance, sublingual tablets and transdermal patches are gaining popularity as they offer quicker relief and improved treatment access for patients suffering from opioid overdoses. However, challenges persist, including the presence of counterfeit drugs and the management of comorbid illnesses such as constipation, which are common in opioid users. The approval of new drugs and the continued innovation in delivery systems will be crucial in addressing these challenges and reducing opioid-related deaths.

Request Free Opioid Rescue Products Market Sample

Market Segmentation

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.

Distribution Channel

  Offline
  Online


Product Type

  Naloxone
  Naltrexone
  Others


Geography

  North America

    US


  Europe

    Germany
    UK
    France
    Spain


  Asia

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

Which is the Largest Segment Driving Market Growth?

The offline segment is estimated to witness significant growth during the forecast period. Opioid rescue products, such as naloxone and naltrexone, play a crucial role in reversing the effects of opioid overdoses and treating opioid addiction. Pharmacies serve as essential distribution channels for these medications, making them easily accessible to the public. Prescriptions and, in certain cases, over-the-counter sales are options for obtaining these life-saving drugs.

Get a glance at the market share of various regions Download the PDF Sample

The offline segment was valued at USD 896.70 million in 2018. Major pharmacy chains significantly contribute to making opioid rescue products readily available. First responders, including paramedics, police officers, emergency medical technicians, and non-emergency medical personnel, are increasingly utilizing opioid rescue products. These professionals are often the first on the scene during an opioid overdose and can administer immediate intervention, which is vital in preventing fatalities. Non-governmental organizations also play a significant role in increasing awareness and providing training on the use of opioid rescue products to first responders and the general public.

Which Region is Leading the Market?

For more insights on the market share of various regions Request Free Sample

North America is estimated to contribute 46% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. The opioid crisis is a major public health concern in North America, affecting both the United States and Canada. In the United States, during the 12 months ending in February 2023, over 105,000 reported opioid overdoses occurred, primarily due to synthetic opioids like illicit fentanyl. This startling figure highlights the importance of having effective opioid rescue products available to counteract the potentially fatal consequences of opioid overdoses. In Canada, the opioid overdose crisis continues to pose a significant threat to individuals, families, and communities. This crisis is considered one of the most severe public health crises in the country's recent history. Between January 2016 and June 2022, there were approximately 32,600 apparent opioid toxicity deaths. Opioid overdoses can lead to respiratory depression and psychological problems, making it crucial to have accessible and efficient opioid rescue products.

Opioid rescue products, such as naloxone and buprenorphine, play a vital role in reversing opioid overdoses. These medications can help restore normal breathing and prevent further harm. The ongoing opioid crisis necessitates the continuous development and availability of these essential treatments. In conclusion, the opioid crisis is a pressing issue in North America, with the US and Canada experiencing high numbers of opioid overdoses and fatalities. Effective opioid rescue products, like naloxone and buprenorphine, are essential in mitigating the devastating effects of opioid overdoses. It is crucial to ensure these treatments are accessible and readily available to those in need.

How do Technavio's company ranking

West Virginia is currently the state with the highest drug overdose death rate in the United States, with 91 deaths per 100,000 population in 2022. Although West Virginia had the highest drug overdose death rate at that time, California was the state where the most people died from drug overdose. In 2022, around 10,952 people in California died from a drug overdose. The main perpetrator Opioids account for the majority of all drug overdose deaths in the United States. Opioids include illegal drugs such as heroin, legal prescription drugs like oxycodone, and illicitly manufactured synthetic drugs like fentanyl. The abuse of opioids has increased in recent years, leading to an increased number of drug overdose deaths. The death rate from heroin overdose hit an all-time high of 4.9 per 100,000 population in 2016 and 2017, but has decreased in recent years. Now, illicitly manufactured synthetic opioids such as fentanyl account for the majority of opioid overdose deaths in the United States. Opioid epidemic The sharp rise in overdose deaths from opioids have led many to declare the United States is currently experiencing an opioid epidemic or opioid crisis. The causes of this epidemic are complicated but involve a combination of a rise in dispensed prescriptions, irresponsible marketing from pharmaceutical companies, a lack of physician-patient communication, increased social acceptance of prescription drugs, and an increased supply of cheap and potent heroin on the streets.

The global opioid overdose treatment market is valued at US$ 1.54 billion in 2024, as revealed in a newly published report by Fact.MR. Over the assessment period (2024 to 2034), the market is forecasted to advance at a CAGR of 7.2% and reach a US$ 3.1 billion by the end of 2034.

Report Attribute	Detail
Opioid Overdose Treatment Market Size (2024E)	US$ 1.54 Billion
Forecasted Market Value (2034F)	US$ 3.1 Billion
Global Market Growth Rate (2024 to 2034)	7.2% CAGR
Market Share of Rehabilitation Centers (2034F)	29.7%
North America Market Share (2034F)	43.9%
India Market Growth Rate (2024 to 2034)	11.2% CAGR
Key Companies Profiled	Amneal Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Biotoscana; Collegium Pharmaceutical; EMS Pharma; Endo International; Ethypharm; Eurofarma; GlaxoSmithKline; Hikma Pharmaceuticals; Johnson & Johnson; Mallinckrodt Pharmaceuticals; Mundipharma; Mylan; Novartis; Pfizer; Purdue Pharma; Sanofi; Stada Arzneimittel; Takeda; Teva Pharmaceuticals.

Country-wise Insights

Attribute	United States
Market Value (2024E)	US$ 577.1 Million
Growth Rate (2024 to 2034)	7.8% CAGR
Projected Value (2034F)	US$ 1.22 Billion

Attribute	Japan
Market Value (2024E)	US$ 70.5 Million
Growth Rate (2024 to 2034)	2.8% CAGR
Projected Value (2034F)	US$ 93.2 Million

Category-wise Insights

Attribute	Opioid Antagonists
Segment Value (2024E)	US$ 502.2 Million
Growth Rate (2024 to 2034)	7.8% CAGR
Projected Value (2034F)	US$ 1.06 Billion

Attribute	Naloxone
Market Value (2024E)	US$ 489.5 Million
Growth Rate (2024 to 2034)	8.6% CAGR
Projected Value (2034F)	US$ 1.11 Billion

Attribute	Rehabilitation Centers
Segment Value (2024E)	US$ 460.1 Million
Growth Rate (2024 to 2034)	7.2% CAGR
Projected Value (2034F)	US$ 920.5 Million

Overview

This dataset contains the number of yearly deaths due to Unintentional Drug Overdoses in the United States at a County Level between 2003-2015. To overcome the limitation of the original dataset, it is merged with population dataset to identify missing combinations and imputation is performed on the dataset taking into account the logical rules of the source dataset. Users can decide the proportion of the imputed values in the dataset by using the provided population and… See the full description on the dataset page: https://huggingface.co/datasets/revanth7667/usa_opioid_overdose.

This data package includes the underlying data to replicate the charts, tables, and calculations presented in Stopping the flow: The effects of US-China cooperation on fentanyl markets and overdose deaths, PIIE Working Paper 25-9.

If you use the data, please cite as:

Noland, Marcus, Julieta Contreras, and Lucas Rengifo-Keller. 2025. Stopping the flow: The effects of US-China cooperation on fentanyl markets and overdose deaths. PIIE Working Paper 25-9. Washington: Peterson Institute for International Economics.

In the past few years the number of deaths from cocaine overdose has risen in the United States, with almost ****** such deaths in 2022. Deaths involving cocaine are more common among males than females, with deaths among males more than double that of females in 2022. It is important to note that many overdose deaths involving cocaine also involve the use of other drugs, in particular opioids, which may contribute to death. Cocaine use Cocaine is one of the most commonly used illicit drugs in the United States. As of 2022, over ** million people had used cocaine in their lifetime, an increase from **** million in 2009. Furthermore, almost *** million people in the U.S. used cocaine in the past year as of 2022. Cocaine use among teens The lifetime prevalence of cocaine use among high school students in the U.S. has decreased in recent years. As of 2022, around *** percent of high school students stated they had used cocaine in their lifetime. Nevertheless, around **** percent of high school students state that cocaine is “fairly easy” or “very easy” to obtain.

Opioids Market Outlook

According to our latest research, the global opioids market size reached USD 23.1 billion in 2024, propelled by the increasing prevalence of chronic pain, rising surgical procedures, and expanding palliative care needs. The market is currently experiencing a compound annual growth rate (CAGR) of 3.6% and is forecasted to attain a value of USD 32.4 billion by 2033. This growth trajectory is underpinned by ongoing innovation in pain management therapies, a rising geriatric population, and the broadening application of opioids in both acute and chronic medical conditions. As per our latest research, these factors collectively drive the expansion and evolution of the global opioids market.

The primary growth driver for the opioids market is the escalating global burden of chronic pain disorders, particularly among the aging population. As life expectancy increases worldwide, the prevalence of age-related degenerative diseases such as osteoarthritis, cancer, and neuropathic pain is on the rise. Opioids remain the cornerstone for managing moderate to severe pain when non-opioid analgesics fail to provide adequate relief. Additionally, the growing number of surgical interventions, both elective and emergency, necessitates effective postoperative pain management, further boosting opioid consumption. The medical community’s ongoing efforts to enhance patient quality of life, especially in palliative and end-of-life care, have also contributed to the sustained demand for opioid medications.

Technological advancements and the introduction of novel opioid formulations have significantly impacted market growth. Pharmaceutical companies are investing in the development of abuse-deterrent formulations (ADFs) to address the risks of misuse, addiction, and overdose associated with traditional opioids. These innovative products aim to maintain therapeutic efficacy while reducing the potential for diversion and abuse, thus gaining regulatory approval and clinical acceptance. Moreover, the expansion of healthcare infrastructure in emerging economies has improved access to opioid medications, enabling better pain management for diverse patient populations. The integration of digital health solutions and telemedicine platforms has also facilitated the prescription and monitoring of opioid use, contributing to more personalized and safer pain management strategies.

Despite the positive growth outlook, the opioids market faces significant challenges due to regulatory scrutiny and the ongoing opioid crisis, particularly in North America. Stringent regulations governing opioid prescription, distribution, and monitoring have been implemented to curb misuse and addiction, leading to a complex and evolving compliance landscape. However, these measures have also prompted the development of alternative pain management approaches and the adoption of multimodal analgesia, which may moderate the growth of traditional opioid sales. Nonetheless, the demand for opioids in developing regions remains robust, driven by unmet medical needs and increasing awareness of pain management options.

Regionally, North America continues to dominate the global opioids market, accounting for the largest share due to high prescription rates, advanced healthcare infrastructure, and a significant patient base with chronic pain conditions. Europe follows closely, supported by favorable reimbursement policies and a well-established regulatory framework. The Asia Pacific region is witnessing the fastest growth, attributed to rising healthcare investments, increasing surgical procedures, and expanding access to pain management therapies. Latin America and the Middle East & Africa are also emerging as important markets, driven by improving healthcare delivery and a growing focus on palliative care. Overall, the regional landscape is characterized by varying regulatory environments, healthcare access, and cultural attitudes toward opioid use.

Product Type Analysis

The product type<

This has pushed the demand for alexipharmic drugs. The alexipharmic drug market valuation is estimated to be a staggering US$ 3.80 billion in 2024 and is slated to reach US$ 6.50 billion by the end of 2034, growing at a decent CAGR of 5.40%.

Attributes	Details
Market Value for 2024	US$ 3.80 billion
Projected Market Value for 2034	US$ 6.50 billion
Value-based CAGR of the Market for 2024 to 2034	5.40%

Category-wise Insights

Attributes	Details
Application	Opioid Overdose
Market Share (2024)	39%

Attributes	Details
Distribution Channel	Hospital Pharmacies
Market Share (2024)	42%

Country-wise Insights

Countries	CAGR (2024 to 2034)
South Korea	8.00%
Japan	7.10%
United Kingdom	6.70%
China	6.30%
United States	5.70%

Snapshot img

Drugs Of Abuse Testing Market Size 2024-2028

The drugs of abuse testing market size is forecast to increase by USD 1.04 billion at a CAGR of 4.5% between 2023 and 2028. The market is experiencing significant growth, driven by increased strategic developments and the growing adoption of advanced information technology and information management solutions. These advancements in instruments enable efficient and accurate testing, reducing turnaround time and enhancing overall productivity. For instance, mass spectrometer and chromatography systems are extensively employed for the qualitative and quantitative analysis of cannabinoids in cannabis strains. However, high costs associated with the implementation and maintenance of these technologies remain a challenge for market expansion. Additionally, stringent regulations and the need for continuous innovation to keep up with emerging drugs of abuse are other key factors shaping the market landscape. Overall, the DoA testing market is expected to continue its growth trajectory, fueled by the need for workplace safety and substance abuse prevention.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

The market is driven by the increasing prevalence of prescription drug abuse, psychostimulants, fentanyl, vaping, and illicit drugs, as well as alcohol. Substance use disorders continue to be a significant public health concern in the US. Forensic laboratories and hospitals are major end-users, diagnostics with epidemiologic investigations and addiction treatment centers also contribute. Vulnerable populations such as the elderly, those with chronic pain, LIMS software, and individuals with opioid medications are key focus areas. Drugs like Fentanyl, psychostimulants, and cannabis/marijuana are common targets for testing.

Moreover, fentanyl, a powerful opioid, has emerged as a significant threat in the market. Its illegally manufactured forms are often mixed with other substances, making it difficult to detect and leading to a high number of overdose deaths. The elderly population is another vulnerable group in the market. They are at a higher risk of substance use disorders due to chronic pain and the misuse of prescription medications. Drug use statistics indicate that psychostimulants, such as cocaine and amphetamines, continue to be popular among certain demographics. Vaping, a newer form of drug delivery, has also gained popularity, particularly among the younger population.

Furthermore, real-time surveillance and epidemiologic investigations play a crucial role in identifying drug-related activity and addressing vulnerabilities in the market. Public awareness campaigns and drug testing mandates are essential tools in preventing substance use disorders and promoting addiction treatment. Cannabis, or marijuana, is another substance of interest in the market. While it is legal for medicinal and recreational use in some states, it is still illegal in others, making testing a necessity for employers and law enforcement agencies. The market is expected to grow due to the increasing need for accurate and reliable testing services. This growth is driven by the rising number of overdose deaths, addiction treatment initiatives, and public awareness campaigns.

In conclusion, the market is a critical component in addressing substance use disorders and promoting public health. It encompasses various sectors, including forensic laboratories and hospitals, and offers testing services for a range of substances, including prescription drugs, illicit drugs, and alcohol. The market is driven by various factors, including the increasing prevalence of substance use disorders, the emergence of new drugs and drug delivery methods, and the need for accurate and reliable testing services.

Market Segmentation

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Product

  Instruments
  Consumables


Geography

  North America

    Canada
    US


  Europe

    Denmark


  Asia

    China
    India


  Rest of World (ROW)

By Product Insights

The instruments segment is estimated to witness significant growth during the forecast period. The market encompasses various systems, analyzers, and devices for detecting and quantifying different drug substances. These tools include breath analyzers, chromatography analyzers, immunoassay analyzers, urine testing devices, and oral fluid testing devices. For example, cannabis testing relies on mass spectrometers and chromatography systems to identify and measure the presence and quantity of cannabinoid compounds. Biotechnology plays a significant role in the market, as the principles of detection and quantification are similar to those used in foo

The largest amount of federal drug control spending was reported for FY 2023 with some 44.2 billion U.S. dollars. The requested funding 2025 is slightly higher. This statistic depicts the total federal drug control spending in the United States from FY 2012 to FY 2025, in million U.S. dollars.

U.S. drug control spending

In the United States, around half of the requested budget for federal drug control spending in 2025 was requested for treatment of substance use disorders; the remaining budget was distributed amongst various governmental departments for prevention, interdiction, and law enforcement. In particular, the largest amount of drug control treatment funding in 2024 within the Department of Health and Human Services was spent by the Centers for Medicare and Medicaid Services, followed by the Substance Abuse and Mental Health Services Administration.

Drug control and the opioid epidemic

The misuse of prescription drugs and the opioid epidemic are a major focus of U.S. drug control strategies and spending. In the U.S., the top controlled prescription drugs distributed are hydrocodone and oxycodone, both potentially addictive opioid analgesics that can be misused and sold illegally. In 2010-2019, efforts to reduce illegal sales of opioid narcotics in the U.S. have managed to reduce the amount of opioids diverted from the legal market by over half. Unfortunately, misusing opioids and synthetic variants such as heroin can be life-threatening; death rates due to opioid overdoses are continuing to rise.

The size of the Opioid Rescue Products Market was valued at USD 2.31 billion in 2024 and is projected to reach USD 4.98 billion by 2033, with an expected CAGR of 11.6% during the forecast period.With growing prevalence of cases due to opioid overdose and with awareness of the urgency of rescue treatment, the market for opioid rescue products is expected to boom rapidly. These are products aimed at rescuing victims from the ill effects of opioids, specifically reversing respiratory depression-a common cause of death among patients suffering from overdose. Such products are typically naloxone-based (an opioid antagonist) and are found in injectable, intranasal, and auto-injector forms, so they are easily accessible to healthcare professionals and the public. The growth in the market is fueled by the opioid crisis, especially in regions such as North America, where opioid addiction and overdose rates have increased manifold. Governments, healthcare organizations, and advocacy groups are working to provide life-saving opioid rescue products to reduce overdose deaths. The increased availability of naloxone through pharmacies, community programs, and harm reduction initiatives has further expanded the market. Regulatory support for the point of distribution of opioid rescue products, in both emergency and community settings, has also sparked growth. Widespread penetration in schools, workplaces, and public domains as part of their harm reduction strategies is another trend in the market.

Digital Naloxone Training App Market Outlook

According to our latest research, the global Digital Naloxone Training App market size reached USD 175.9 million in 2024, reflecting the rapid digitization of opioid overdose response training. The market is projected to expand at a robust CAGR of 18.2% from 2025 to 2033, reaching a forecasted value of USD 822.1 million by 2033. The primary growth driver for this market is the increasing global awareness of opioid overdose risks and the urgent need for scalable, accessible training solutions to empower both professionals and the public in life-saving naloxone administration.

One of the most significant growth factors for the Digital Naloxone Training App market is the alarming rise in opioid-related overdose deaths worldwide, particularly in North America and parts of Europe. Governments, health organizations, and advocacy groups are intensifying efforts to combat this crisis through education, rapid response, and harm reduction strategies. Digital naloxone training apps have emerged as a crucial tool, offering interactive, evidence-based modules that can be accessed anytime and anywhere. These solutions overcome traditional barriers to training, such as geographic limitations, scheduling conflicts, and resource constraints. As more jurisdictions mandate naloxone training for healthcare professionals, first responders, and even the general public, demand for digital platforms is expected to surge, further propelling market growth.

Another key driver is the advancement of mobile health technologies and the increasing penetration of smartphones and internet connectivity. The shift toward digital health solutions, accelerated by the COVID-19 pandemic, has made remote and on-demand training not only feasible but also preferable in many cases. Digital naloxone training apps leverage multimedia content, interactive simulations, and real-time feedback to enhance user engagement and retention of critical skills. Integration with wearable devices, telehealth platforms, and electronic health records is also on the rise, providing a holistic approach to overdose prevention and response. This technological evolution is attracting investments from both public and private sectors, fostering innovation and expanding the reach of these training solutions.

A third growth factor is the expanding scope of end-users beyond traditional healthcare settings. While initial adoption was driven by hospitals and clinics, there is now a growing emphasis on equipping community health centers, educational institutions, and even workplaces with naloxone training resources. Public health campaigns and corporate social responsibility initiatives are increasingly incorporating digital naloxone training to address the opioid crisis at a community level. This broadening of the user base not only drives market expansion but also enhances the societal impact of these apps, contributing to a more informed and prepared population.

From a regional perspective, North America continues to dominate the Digital Naloxone Training App market, accounting for over 45% of the global revenue in 2024. The region’s leadership is attributed to high opioid overdose rates, proactive government policies, and a mature digital health ecosystem. Europe follows, with significant growth in countries like the United Kingdom, Germany, and France, where public health authorities are adopting digital solutions to combat the opioid epidemic. The Asia Pacific region, while currently accounting for a smaller market share, is poised for the highest CAGR over the forecast period, driven by increasing awareness, improving healthcare infrastructure, and growing smartphone adoption. Latin America and the Middle East & Africa are also witnessing gradual uptake, supported by international aid and pilot programs.

Component Analysis

The Digital Naloxone Training App market is segmented by component into software and services, each playing a pivotal role in the delivery and effectiveness of

Nalmefene Hydrochloride Market Outlook

As per our latest research, the nalmefene hydrochloride market size globally reached USD 1.24 billion in 2024. The market is poised to grow at a robust CAGR of 8.2% during the forecast period, with the market expected to reach USD 2.39 billion by 2033. The primary growth driver for this market is the rising prevalence of alcohol dependence and opioid overdose cases worldwide, coupled with increasing awareness about harm reduction therapies. Additionally, advancements in drug delivery formulations and the expanding role of nalmefene hydrochloride in diverse clinical settings are further propelling market expansion.

A significant growth factor for the nalmefene hydrochloride market is the alarming increase in alcohol use disorders and opioid misuse globally. According to recent World Health Organization (WHO) statistics, over 283 million people suffer from alcohol use disorders, while opioid overdose remains a critical public health crisis, particularly in North America and parts of Europe. Nalmefene hydrochloride, with its unique pharmacological profile as an opioid receptor modulator, has gained traction as an effective intervention for reducing alcohol consumption and reversing opioid overdoses. The growing acceptance of medication-assisted therapies (MAT) for substance use disorders, coupled with supportive government policies and funding, has significantly boosted the adoption of nalmefene-based products across healthcare systems.

Another crucial driver is the ongoing innovation in drug formulations and delivery mechanisms. Pharmaceutical companies are actively investing in the development of extended-release tablets, injectable forms, and combination therapies to enhance patient compliance and therapeutic outcomes. The introduction of user-friendly dosage forms, such as orally disintegrating tablets and pre-filled injectable pens, has made nalmefene hydrochloride more accessible, especially in emergency and outpatient settings. These innovations not only improve the efficacy and safety profile of the drug but also expand its utility across various patient demographics, including those with comorbidities or difficulty with traditional oral medications. This trend is expected to continue, further fueling market growth throughout the forecast period.

Furthermore, the increasing integration of digital health platforms and telemedicine in addiction treatment is augmenting the reach of nalmefene hydrochloride therapies. With the proliferation of online pharmacies and digital prescription services, patients now have greater access to essential medications, irrespective of geographical constraints. This digital transformation is particularly beneficial for remote and underserved populations, where traditional healthcare infrastructure may be lacking. Additionally, rising public and private investment in mental health and addiction treatment programs, alongside a shift towards evidence-based interventions, is creating a favorable environment for the expansion of the nalmefene hydrochloride market on a global scale.

From a regional perspective, North America currently dominates the nalmefene hydrochloride market, accounting for the largest share in 2024, followed closely by Europe. The Asia Pacific region is witnessing the fastest growth, attributed to increasing healthcare expenditure, growing awareness about substance use disorders, and the gradual alignment of regulatory frameworks with international standards. Meanwhile, emerging markets in Latin America and the Middle East & Africa are also experiencing steady growth, driven by improving access to healthcare services and the gradual destigmatization of addiction treatment. This dynamic regional landscape underscores the global relevance and expanding footprint of nalmefene hydrochloride across diverse healthcare ecosystems.

Product Type Analysis

The nalmefene hydrochloride market by product type is segmented into tablets, injections, and others. Among these, tablets ho

BASE YEAR	2024
HISTORICAL DATA	2019 - 2024
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
MARKET SIZE 2023	749.35(USD Billion)
MARKET SIZE 2024	754.22(USD Billion)
MARKET SIZE 2032	793.84(USD Billion)
SEGMENTS COVERED	Indication ,Device Design ,Flow Rate ,Area of Application ,Regional
COUNTRIES COVERED	North America, Europe, APAC, South America, MEA
KEY MARKET DYNAMICS	Increasing prevalence of sepsis growing demand for extracorporeal therapies technological advancements surging geriatric population rising healthcare expenditure
MARKET FORECAST UNITS	USD Billion
KEY COMPANIES PROFILED	Polypore International ,Getinge ,CytoSorbents ,Jafron Biomedical ,Baxter ,Medtronic ,Toray Industries ,Terumo BCT ,Asahi Kasei Medical ,Pall Corporation ,B. Braun Melsungen ,Kaneka Corporation ,Edwards Lifesciences ,Maquet ,Fresenius Medical Care
MARKET FORECAST PERIOD	2025 - 2032
KEY MARKET OPPORTUNITIES	Rising prevalence of sepsis Technological advancements Increasing awareness of hemoperfusion therapy Growing geriatric population Expanding applications in critical care
COMPOUND ANNUAL GROWTH RATE (CAGR)	0.65% (2025 - 2032)